Article
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Annals of hematology - 1 Nov 2010
Buda Gabriele, Ricci Deborah, Huang C Chris, Favis Reyna, Cohen Nadine, Zhuang Sen H, Harousseau Jean-Luc, Sonneveld Pieter, Bladé Joan, Orlowski Robert Z
Abstract excerpt
Single nucleotide polymorphisms (SNPs) in the multiple drug resistance protein 1 (MRP1) and P-glycoprotein 1 (MDR1) genes modulate their ability to mediate drug resistance. We therefore sought to retrospectively evaluate their influence on outcomes in relapsed and/or refractory myeloma patients t...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.